The Tennessee Board of Medical Examiners revoked the license of a family physician with more than 25 years experience for prescribing medication to patients without proper justification. Sidi Yousseff Noor practiced at Holston Medical Group, an urgent care clinic with locations in and around Kingston, Tenn. The order claims Noor prescribed drugs including Actiq, Morphine and Ketamine to approximately 75 patients without proper justification while working at Crescent Medical Center in Morristown.

The Tennessee Department of Health disciplinary action report states that Noor’s license was revoked because he was found to have been engaged in professional misconduct, gross malpractice, failed to attempt to cure patients’ addictions to controlled substances, and failed to establish prior justification for issuing certain prescriptions to patients.

All three drugs for which Noor was cited for prescribing are potent anesthetics or painkillers. Actiq, in particular, is a form of fentanyl citrate, an opioid narcotic more powerful than morphine. Administered as a lollipop lozenge, Actiq was approved by the Food and Drug Administration (FDA) for very limited use in the treatment of breakthrough pain in cancer patients who had built up a tolerance to opioids. However, some doctors began prescribing Actiq to non-cancer patients for management of pain from migraines or headaches.

Capitalizing on the trend, Cephalon, the makers of Actiq, began promoting this off-label use, even telling doctors that the cancer drug could be used for backaches and injuries. A 2007 study by Prime Therapeutics showed that Cephalon’s marketing practices paid off. The study found that Actiq was used 90 percent of the time for these unapproved uses. But Actiq was never meant for patients who had not built up a tolerance to opioids, and serious problems soon followed. Actiq has since been linked to 127 deaths and 91 incidents of severe side effects. Both the FDA’s Office of Criminal Investigations and the U.S. Attorney General launched an investigation into Cephalon’s marketing practices.



We're here to help!

We live by our creed of "helping those who need it most" and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked    may be required for submission.
  1. I'm an attorney

Fentanyl patches recalled due to accelerated release...

Potent pain patches used to treat breakthrough pain in cancer patients already on around-the-clock pain...

Fentanyl patches recalled due to danger of overdose

Potent pain patches used to treat breakthrough pain in cancer patients already on around-the-clock pain...

Cephalon files petition to block Fentora competition

Cephalon, maker of the potent pain killer Fentora, has filed a citizen petition to the Food and Drug...

56 dead from one clinic after taking Actiq for...

Fifty-six patients from one health care clinic have died and 96 others were sent to the emergency room...

FDA approves painkiller designed to be more difficult...

The Food and Drug Administration (FDA) has approved a new version of the painkiller OxyContin that is...

Types of potent painkillers approved only with...

When the Food and Drug Administration (FDA) approved the new opioid medication, Onsolis, last summer,...

Thank you for all your hard work

Thank you for all your hard work over the past years on my behalf and so many others. God bless you all.

—Ella